Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 885 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Diagnosed Alone October 6, 2020 No improvement in OS, but more grade 3 or higher AEs... September 24, 2026 Coronavirus reports – Part 7: “I’m more concerned about the second... November 24, 2020 Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer May 21, 2024 Load more HOT NEWS ¿Tener paneles solares o vivir cerca de una granja solar puede... Your Microbiome and Cancer: What to Know New Research Looks for More Effective Breast Cancer Treatments for Black... Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma...
